Strides arm commences construction of $ 60 mn Malaysia plant.

Stelis Biopharma, a wholly-owned arm of Strides Arcolab, has commenced construction of its Rs. 370 crore ($60 million) biologics facility at Malaysia.

Stelis has entered into a build and lease agreement with Bio-XCell for the construction of 1,40,000 sq feet facility at Johor, Malaysia which is expected to be completed in next 24 months, Strides Arcolab said in a statement.

The facility will incorporate next—gen single use bio-processing technology with both mammalian and microbial manufacturing suites, it added.

Stelis Biopharma CEO, Joe Thomas said: 'With its strong commitment to bio-economy, attractive incentives, quality infrastructure and enabling ecosystem, we are confident of making this our bio-manufacturing hub for regional and global markets'.

The facility will employ 180 people in R&D and manufacturing.


HBL